InnoCare Pharma (9969) Q4 2024 earnings summary

Executive summary

• Orelabrutinib sales surpassed RMB 1 billion, growing 49.1% year-over-year and driving robust commercial acceleration and financial improvement.

• Loss for the year narrowed by 29.9% to RMB 453 million, supported by strong drug sales, cost efficiency, and reduced non-cash expenses.

• Maintained strong cash reserves of RMB 7.8 billion at year-end, providing flexibility for R&D and business development.

• Diversified late-stage pipeline in oncology, autoimmune diseases, and solid tumors, with multiple Phase 3 studies and global expansion initiatives.

• Gross profit margin increased to 86.3% from 82.6% year-over-year, reflecting improved manufacturing efficiency and favorable sales mix.

Financial highlights

• Drug sales revenue grew 49.7% to RMB 1,005.6 million in 2024, mainly driven by orelabrutinib.

• Total revenue rose 36.7% to RMB 1,009.4 million; gross profit increased 42.8% to RMB 871 million.

• Net loss narrowed by 29.9% to RMB 453 million, with loss per share improving to RMB 0.26.

• R&D expenses rose 8.4% to RMB 814 million, supporting accelerated clinical trials and technology platforms.

• Cash and related balances at year-end were RMB 7.8 billion, with annual net cash consumption of RMB 524 million.

Outlook and guidance

• Expects at least 30% sales growth in 2025, with MZL indication contributing up to 50% of orelabrutinib sales.

• NDA submissions and regulatory milestones anticipated for tafasitamab, orelabrutinib (1L CLL/SLL), and zurletrectinib in 2025.

• Multiple Phase 3 trials ongoing or starting for key assets in hemato-oncology, autoimmune, and solid tumor indications.

• Strategic priorities include global expansion, accelerating partnerships, and leveraging AI for R&D efficiency.

• Key milestones in the next 12 months include NDA/BLA submissions and clinical trial completions across major assets.